Latest & greatest articles for tuberculosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on tuberculosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on tuberculosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for tuberculosis

141. Macrophage migration inhibitory factor -173 G > C polymorphism and risk of tuberculosis: A meta-analysis. (PubMed)

Macrophage migration inhibitory factor -173 G > C polymorphism and risk of tuberculosis: A meta-analysis. The aim of the present meta-analysis was to find out the impact of MIF -173 G > C polymorphism on risk of tuberculosis (TB). We conducted a search of case-control studies on the associations of -173 G > C variant of MIF with susceptibility to tuberculosis in PubMed, ISI Web of Science, and Scopus. We extracted the data from eligible studies and achieved a meta-analysis to examine

Full Text available with Trip Pro

2017 EXCLI journal

142. User experience analysis of e-TB Manager, a nationwide electronic tuberculosis recording and reporting system in Ukraine (PubMed)

User experience analysis of e-TB Manager, a nationwide electronic tuberculosis recording and reporting system in Ukraine Ukraine has successfully implemented e-TB Manager nationwide as its mandatory national tuberculosis registry after first introducing it in 2009. Our objective was to perform an end-of-programme evaluation after formal handover of the registry administration to Ukraine's Centre for Disease Control in 2015. We conducted a nationwide, cross-sectional, anonymous, 18-point user (...) received and satisfaction with the registry. Of the 5.9 million transactions over a 4-year period, nine out of 24 oblasts (regions) and Kiev city accounted for 62.5% of all transactions, and corresponded to 59% of Ukraine's tuberculosis burden. There were 437 unique active users in 486 rayons (districts) of Ukraine, demonstrating extensive reach. Our key findings complement the World Health Organization and European Respiratory Society's agenda for action on digital health to help implement the End TB

Full Text available with Trip Pro

2017 ERJ open research

143. FluoroType MTB system for the detection of pulmonary tuberculosis (PubMed)

FluoroType MTB system for the detection of pulmonary tuberculosis FluoroType MTB is a sensitive test for TB but specificity is low compared with fully integrated molecular systems http://ow.ly/WhEO30b1luY.

Full Text available with Trip Pro

2017 ERJ open research

144. Synchronous Colon Carcinoma and Tuberculosis: Coincidence or Linked (PubMed)

Synchronous Colon Carcinoma and Tuberculosis: Coincidence or Linked How to cite this article: Dayal S. Synchronous Colon Carcinoma and Tuberculosis: Coincidence or Linked. Euroasian J Hepato-Gastroenterol 2017;7(1):97-98.

Full Text available with Trip Pro

2017 Euroasian journal of hepato-gastroenterology

145. Do incentives and enablers improve adherence to tuberculosis treatment?

Do incentives and enablers improve adherence to tuberculosis treatment? Do incentives and enablers improve adherence to tuberculosis treatment? - NIPH Selected items added to basket Close Search for: Søk Meny Infectious diseases & Vaccines Close Mental & Physical health Close Environment & Lifestyle Close Health in Norway Close Quality & Knowledge Close Research & Access to data Close About NIPH Close Do incentives and enablers improve adherence to tuberculosis treatment? Fact sheet Have you (...) found an error? Key message What does the research show? The diagnosis and treatment of people with tuberculosis is critical for curing the disease, controlling infection and minimising drug resistance. The aim of this Cochrane Review was to find out if people were more likely to return for diagnosis appointments and follow their treatment when receiving material incentives and enablers. Cochrane authors collected and analysed all relevant research studies to answer this question. The Cochrane

2017 Norwegian Institute of Public Health

146. Renal Transplant–Associated Thyroid Tuberculosis (PubMed)

Renal Transplant–Associated Thyroid Tuberculosis Tuberculosis is common among solid-organ transplant recipients, including renal transplants. Tuberculosis of the thyroid gland is a rare diagnosis. We report on a renal transplant recipient with subacute fever associated with a neck mass diagnosed as thyroid tuberculosis. No prior publication has reported a case of posttransplant thyroid tuberculosis. This is an important diagnostic consideration, in addition to malignant transformation

Full Text available with Trip Pro

2017 Journal of the Endocrine Society

147. Delamanid (Deltyba) and multidrug-resistant pulmonary tuberculosis. For selected patients, with cardiac monitoring

Delamanid (Deltyba) and multidrug-resistant pulmonary tuberculosis. For selected patients, with cardiac monitoring Prescrire IN ENGLISH - Spotlight ''Delamanid (Deltyba°) and multidrug-resistant pulmonary tuberculosis. For selected patients, with cardiac monitoring'', 1 April 2017 {1} {1} {1} | | > > > Delamanid (Deltyba°) and multidrug-resistant pulmonary tuberculosis. For selected patients, with cardiac monitoring Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent (...) :  |   |   |   |   |   |   |   |   |  Spotlight Delamanid (Deltyba°) and multidrug-resistant pulmonary tuberculosis. For selected patients, with cardiac monitoring FEATURED REVIEW Despite delamanid's rather shaky evaluation, the available data suggest that this antibiotic should be offered to patients with multidrug-resistant tuberculosis. The noteworthy impact of delamanid on the QT interval warrants electrocardiographic

2017 Prescrire

148. The mask of acute bacterial pneumonia may disguise the face of tuberculosis (PubMed)

The mask of acute bacterial pneumonia may disguise the face of tuberculosis Pulmonary tuberculosis (TB) can present as acute pneumonia. Differentiation of tuberculous from non-tuberculous community-acquired pneumonia (CAP) is an important challenge in endemic areas. The purpose of this study was the comparison between characteristics of tuberculous and non-tuberculous CAP patients.In this prospective and observational study, all adult patients (aged ≥16 years) who were admitted to Imam Reza

Full Text available with Trip Pro

2017 Electronic physician

149. India's plan to eliminate tuberculosis by 2025: converting rhetoric into reality (PubMed)

India's plan to eliminate tuberculosis by 2025: converting rhetoric into reality 28589035 2018 11 13 2059-7908 2 2 2016 BMJ global health BMJ Glob Health India's plan to eliminate tuberculosis by 2025: converting rhetoric into reality. e000326 10.1136/bmjgh-2017-000326 Pai Madhukar M McGill Global Health Programs & McGill International TB Centre, McGill University, Montreal, Canada. Manipal McGill Centre for Infectious Diseases, Manipal University, Manipal, India. Bhaumik Soumyadeep S BMJ

Full Text available with Trip Pro

2017 BMJ global health

150. The bacillary and macrophage response to hypoxia in tuberculosis and the consequences for T cell antigen recognition (PubMed)

The bacillary and macrophage response to hypoxia in tuberculosis and the consequences for T cell antigen recognition Mycobacterium tuberculosis is a facultative anaerobe and its characteristic pathological hallmark, the granuloma, exhibits hypoxia in humans and in most experimental models. Thus the host and bacillary adaptation to hypoxia is of central importance in understanding pathogenesis and thereby to derive new drug treatments and vaccines.Copyright © 2016 The Author(s). Published

Full Text available with Trip Pro

2017 Microbes and infection

151. Fumarase deficiency causes protein and metabolite succination and intoxicates Mycobacterium tuberculosis (PubMed)

Fumarase deficiency causes protein and metabolite succination and intoxicates Mycobacterium tuberculosis Enzymes of central carbon metabolism are essential mediators of Mycobacterium tuberculosis (Mtb) physiology and pathogenicity, but are often perceived to lack sufficient species selectivity to be pursued as potential drug targets. Fumarase (Fum) is an enzyme of the canonical tricarboxylic acid cycle and is dispensable in many organisms. Transposon mutagenesis studies in Mtb, however

Full Text available with Trip Pro

2017 Cell chemical biology

152. Tuberculosis. (PubMed)

Tuberculosis. This issue provides a clinical overview of tuberculosis, focusing on screening, prevention, diagnosis, and treatment. The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), including MKSAP (Medical Knowledge and Self-Assessment Program). Annals of Internal Medicine editors develop In the Clinic in collaboration with the ACP's Medical Education and Publishing divisions and with the assistance

2017 Annals of Internal Medicine

153. Interventions to improve contact tracing for tuberculosis in specific groups and in wider populations: an evidence synthesis

Interventions to improve contact tracing for tuberculosis in specific groups and in wider populations: an evidence synthesis Interventions to improve contact tracing for tuberculosis in specific groups and in wider populations: an evidence synthesis Interventions to improve contact tracing for tuberculosis in specific groups and in wider populations: an evidence synthesis Baxter S, Goyder E, Chambers D, Johnson M, Preston L & Booth A. Record Status This is a bibliographic record of a published (...) health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Baxter S, Goyder E, Chambers D, Johnson M, Preston L & Booth A.. Interventions to improve contact tracing for tuberculosis in specific groups and in wider populations: an evidence synthesis. Health Services and Delivery Research 2017; 5(1) Authors' objectives The tracing and screening of people who have had contact with an active case of tuberculosis (TB

2017 Health Technology Assessment (HTA) Database.

154. Multiple large clusters of tuberculosis in London: a cross-sectional analysis of molecular and spatial data (PubMed)

Multiple large clusters of tuberculosis in London: a cross-sectional analysis of molecular and spatial data Large outbreaks of tuberculosis (TB) represent a particular threat to disease control because they reflect multiple instances of active transmission. The extent to which long chains of transmission contribute to high TB incidence in London is unknown. We aimed to estimate the contribution of large clusters to the burden of TB in London and identify risk factors. We identified TB patients

Full Text available with Trip Pro

2017 ERJ open research

155. Who pays for cooperation in global health? A comparative analysis of WHO, the World Bank, the Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria, and Gavi, the Vaccine Alliance. (PubMed)

Who pays for cooperation in global health? A comparative analysis of WHO, the World Bank, the Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria, and Gavi, the Vaccine Alliance. In this report we assess who pays for cooperation in global health through an analysis of the financial flows of WHO, the World Bank, the Global Fund to Fight HIV/AIDS, TB and Malaria, and Gavi, the Vaccine Alliance. The past few decades have seen the consolidation of influence in the disproportionate roles the USA

Full Text available with Trip Pro

2017 Lancet

156. Transmission of Extensively Drug-Resistant Tuberculosis in South Africa. (PubMed)

Transmission of Extensively Drug-Resistant Tuberculosis in South Africa. Drug-resistant tuberculosis threatens recent gains in the treatment of tuberculosis and human immunodeficiency virus (HIV) infection worldwide. A widespread epidemic of extensively drug-resistant (XDR) tuberculosis is occurring in South Africa, where cases have increased substantially since 2002. The factors driving this rapid increase have not been fully elucidated, but such knowledge is needed to guide public health (...) interventions.We conducted a prospective study involving 404 participants in KwaZulu-Natal Province, South Africa, with a diagnosis of XDR tuberculosis between 2011 and 2014. Interviews and medical-record reviews were used to elicit information on the participants' history of tuberculosis and HIV infection, hospitalizations, and social networks. Mycobacterium tuberculosis isolates underwent insertion sequence (IS)6110 restriction-fragment-length polymorphism analysis, targeted gene sequencing, and whole-genome

Full Text available with Trip Pro

2017 NEJM

157. The impact of ISGylation during Mycobacterium tuberculosis infection in mice (PubMed)

The impact of ISGylation during Mycobacterium tuberculosis infection in mice Mycobacterium tuberculosis infection results in 1.5 million deaths annually. Type I interferon (IFN) signaling through its receptor IFNAR correlates with increased severity of disease, although how this increases susceptibility to M. tuberculosis remains uncertain. ISG15 is one of the most highly induced interferon stimulated genes (ISGs) during M. tuberculosis infection. ISG15 functions by conjugation to target (...) proteins (ISGylation), by noncovalent association with intracellular proteins, and by release from the cell. Recent studies indicated that ISG15 can function via conjugation-independent mechanisms to suppress the type I IFN response. These data raised the question of whether ISG15 may have diverse and sometimes opposing functions during M. tuberculosis infection. To address this, we analyzed ISGylation during M. tuberculosis infection and show that ISGylated proteins accumulate following infection

Full Text available with Trip Pro

2017 Microbes and infection

158. Choroidal neovascularization secondary to tuberculosis: Presentation and management (PubMed)

Choroidal neovascularization secondary to tuberculosis: Presentation and management While there are many known etiologies of choroidal neovascularization (CNV), tuberculosis is not a well-known causative agent. In this case series, we highlight CNV occurring secondary to tuberculous chorioretinitis, its presentation, and its management.We retrospectively reviewed the charts and imaging of four patients who presented with presumed tuberculous chorioretinitis and CNV. Three of these patients had (...) signs of intraocular inflammation and were also found to have active macular CNV. The one remaining patient had chorioretinal scars from prior posterior uveitis and previously treated macular CNV membranes. The three patients with active disease were started on anti-tuberculosis medications and oral corticosteroids, and they also received intravitreal anti-vascular endothelial growth factor (VEGF) injections as needed for the CNV. There was a significant improvement in the clinical course of all

Full Text available with Trip Pro

2017 American journal of ophthalmology case reports

159. Roadmap for Zoonotic Tuberculosis

Roadmap for Zoonotic Tuberculosis FOR ZOONOTIC ROADMAP TUBERCULOSISRoadmap for zoonotic tuberculosis © World Health Organization (WHO), Food and Agriculture Organization of the United Nations (FAO) and World Organisation for Animal Health (OIE), 2017 ISBN 978-92-4-151304-3 (WHO) ISBN 978-92-5-109927-8 (FAO) ISBN 978-92-95108-51-6 (OIE) Publications of the World Health Organization are available on the WHO web site www.who.int or can be purchased from WHO Press, World Health Organization, 20 (...) Togami (The Union), Rea Tschopp (Swiss Tropical and Public Health Institute, Switzerland and Armauer Hansen Research Institute, Ethiopia), Paul van Helden (Stellenbosch University, South Africa), Angela Varnum (Colorado State University, USA), Jakob Zinsstag (Swiss Tropical and Public Health Institute, Switzerland) Production of this document was supported by a financial contribution from The International Union Against Tuberculosis and Lung Disease through U.S. Centers for Disease Control

2017 International Union Against TB and Lung Disease

160. Handbook for the use of digital technologies to support tuberculosis medication adherence

Handbook for the use of digital technologies to support tuberculosis medication adherence Handbook for the use of digital technologies to support tuberculosis medication adherence JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links Handbook for the use of digital technologies to support tuberculosis medication adherence View/ Open Rights View Statistics Altmetrics Share Citation (...) World Health Organization . (‎2017)‎. Handbook for the use of digital technologies to support tuberculosis medication adherence. World Health Organization. . License: CC BY-NC-SA 3.0 IGO Description vi, 50 p. Gov't Doc # WHO/HTM/TB/2017.30 ISBN 9789241513456 Collections Language English Metadata Related items Showing items related by title and MeSH subject.  Organisation mondiale de la Santé (‎ WHO/HTM/TB/2014.1 , 2014 )‎  Всемирная организация здравоохранения (‎ WHO/FWC/WSH/17.05 , 2017

2017 WHO